ERN eUROGEN ePAG Chair at EMUC26: Penile Cancer Patient Survey Update

ERN eUROGEN ePAG Chair at EMUC26: Penile Cancer Patient Survey Update

EMUC26 flag and Welcome to EMUC26 banner at the glass entrance of the congress centre in BrusselsOn Friday 6 November 2026, John Osborne, Chair of the ERN eUROGEN European Patient Advocacy Group (ePAG), was invited to Brussels to take part in the plenary session “Reducing toxicity while maintaining efficacy” at the 18th European Multidisciplinary Congress on Urological Cancers (EMUC26). He opened the session’s penile cancer section with an update on the Penile Cancer Patient Survey.

About EMUC26

EMUC26 is a collaboration between the European Association of Urology (EAU), the European Society of Radiology (ESR), the European Association of Nuclear Medicine (EANM) and the European Society for Radiotherapy and Oncology (ESTRO). The congress combines essential updates on genitourinary cancers, thought-provoking case-study discussions, and practical training and workshops. The emphasis is on joint working and the benefits that can arise from multidisciplinary work.

“Uro-oncology is teamwork,” said Prof. Barbara Jereczek-Fossa (President of ESTRO), speaking ahead of the congress. “EMUC26 perfectly embodies this spirit of collaboration. It’s a unique environment where innovation, evidence, and real-world practice from diverse disciplines come together.”

What the penile cancer survey found

The survey is an initiative supported by ERN eUROGEN, the EAU Patient Office and Orchid Male Cancer (UK). It gives patients an opportunity to give feedback on their experience of penile cancer, from awareness of this extremely rare disease to diagnosis, treatment, survivorship and quality of life. The survey has highlighted some key findings that show the very real challenges patients face. These include delays in getting a diagnosis (51% of respondents waited more than a month, and 15% more than six months) and a decline in quality of life (93% had a good quality of life before treatment, compared with 48% after treatment). In addition, 58% were offered no psychological support, and 28% of respondents have considered taking their own life.

If you have been affected by penile cancer and are finding things difficult, please talk to your healthcare team. If you are having thoughts of suicide, you can find free, confidential support in your country through Find A Helpline. In the UK, Orchid’s National Male Cancer Helpline (0808 802 0010) offers support from specialist nurses.

John Osborne on stage at EMUC26 beside his closing slide after presenting the penile cancer survey update

“Don’t fix us if you leave us broken”

Putting patients at the centre

“It was an honour to be asked to contribute to the congress,” said John, “and it is a measure of the commitment of the leading figures within the penile cancer world to being truly patient-centred. In the last two iterations of the EAU-ASCO Penile Cancer Guidelines, there has been concerted action to put the patient experience front and centre, not only in the guidelines themselves but in the committee’s approach to how it works. It is gratifying to see this approach being applied to such important forums as EMUC26.”

How to take part in the penile cancer survey

If you work with men who have experienced penile cancer, please encourage them to complete the survey, which is available in 15 languages.

➡️ Complete the Penile Cancer Patient Survey